Amendment 1 to License AgreementLicense Agreement • September 28th, 2023 • Apollomics Inc. • Pharmaceutical preparations
Contract Type FiledSeptember 28th, 2023 Company IndustryEdison Oncology Holding Corp. (“Edison”) and Apollomics Inc. (“Apollomics”) previously entered into a License Agreement dated January 31, 2021 (“License Agreement”), for the purpose of developing, seeking regulatory approval and commercializing EO1001. Edison and Apollomics are also referred to individually as a “Party” and together as the “Parties”;